0.210
0.000
(0.00%)
Jun 17 - Close
CVE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | - |
| 52 week | 0.19 - 0.39 |
| Open | - |
| Vol / Avg. | 0.00/3,334.00 |
| Mkt cap | 14.26M |
| P/E | - |
| Div/yield | - |
| EPS | -0.07 |
| Shares | 67.90M |
| Beta | - |
| Inst. own | - |
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -468.29% | -1540.51% |
| Operating margin | -422.24% | -1364.19% |
| EBITD margin | - | -943.04% |
| Return on average assets | -159.31% | -316.77% |
| Return on average equity | - | - |
| Carbon Disclosure Rating | - | - |
Address
245-2650 Queensview Drive
OTTAWA, ON K2B 8H6
Canada
+1-519-6721524 (Phone)
+1-519-6726950 (Fax)
OTTAWA, ON K2B 8H6
Canada
+1-519-6721524 (Phone)
+1-519-6726950 (Fax)
External links
Discussion Group - Google Finance
Advertisement
Description
Annidis Corporation, formerly Aumento Capital Corporation, is engaged in researching and developing instrumentation to assist in the early detection and monitoring of diseases of the eye. The Company�s RHA is an ocular pathology management system that integrates advanced multi-spectral imaging and analytic software for early detection and management of ocular pathologies, such as glaucoma, agerelated macular degeneration and diabetic retinopathy. On June 9, 2011, the Company completed the qualifying transaction by acquiring Annidis Health Systems Corp. The Company was formerly a capital pool company.
Officers and directors
| Michael Mueller | Chairman of the Board | |
| Zeljko Ribaric | President, Director | |
| Gerald Slemko | Chief Executive Officer, Director | |
| Brian Baker | Chief Financial Officer | |
| Michael Crowley | Independent Director | |
| Robert G. Devenyi | Independent Director | |
| Rony Thomas | Independent Director |